Tanaka Atsushi, Suzuki Youichi
Division of Research Animal Laboratory and Translational Medicine, Research and Development Center, Osaka Medical and Pharmaceutical University, Takatsuki, Japan.
Department of Microbiology and Infection Control, Faculty of Medicine, Osaka Medical and Pharmaceutical University, Takatsuki, Japan.
Front Microbiol. 2022 Mar 24;13:866271. doi: 10.3389/fmicb.2022.866271. eCollection 2022.
Chikungunya virus (CHIKV), the causative agent of Chikungunya fever (CHIKVF) that is often characterized by fever, headache, rash, and arthralgia, is transmitted to humans by mosquito bites. Although the mortality rate associated with CHIKV infection is not very high, CHIKVF has been confirmed in more than 40 countries, not only in tropical but also in temperate areas. Therefore, CHIKV is a growing major threat to the public health of the world. However, a specific drug is not available for CHIKV infection. As demonstrated by many studies, the processes completing the replication of CHIKV are assisted by many host factors, whereas it has become clear that the host cell possesses some factors limiting the virus replication. This evidence will provide us with an important clue for the development of pharmacological treatment against CHIKVF. In this review, we briefly summarize cellular molecules participating in the CHIKV infection, particularly focusing on introducing recent genome-wide screen studies that enabled illuminating the virus-host interactions.
基孔肯雅病毒(CHIKV)是基孔肯雅热(CHIKVF)的病原体,通常表现为发热、头痛、皮疹和关节痛,通过蚊虫叮咬传播给人类。尽管与CHIKV感染相关的死亡率不是很高,但CHIKVF已在40多个国家得到确认,不仅在热带地区,也在温带地区。因此,CHIKV对全球公共卫生构成的威胁日益严重。然而,目前尚无针对CHIKV感染的特效药物。许多研究表明,CHIKV复制过程由许多宿主因子协助完成,而宿主细胞显然也拥有一些限制病毒复制的因子。这一证据将为我们开发针对CHIKVF的药物治疗提供重要线索。在这篇综述中,我们简要总结了参与CHIKV感染的细胞分子,尤其着重介绍了近期能够阐明病毒与宿主相互作用的全基因组筛选研究。